Gene expression in tumor and adjacent normal tissues in lung adenocarcinoma subtypes
- PMID: 40660181
- PMCID: PMC12261662
- DOI: 10.1186/s12885-025-14496-z
Gene expression in tumor and adjacent normal tissues in lung adenocarcinoma subtypes
Abstract
Background: Lung adenocarcinoma (LUAD) has several histologically distinct subtypes that differ by a number of clinical features including patient survival. Molecular mechanisms underlying histological and clinical differences between subtypes remain poorly understood.
Methods: We conducted a comparative analyses of gene expression in acinar, lepidic, papillary and solid subtypes, as well as mucinous adenocarcinoma. We used a novel, more efficient approach to identify subtype-specific genes. We compared the mean gene expression level separately for tumors and adjacent normal tissue with pure or a highly represented (≥ 75%) subtype of interest to the mean expression in tumors where the subtype of interest was not present. We also performed tumor to adjacent normal tissue comparisons and identified genes differentially expressed between tumor and adjacent normal tissues for each subtype.
Results: The number of subtype-specific genes varied from 1 for the acinar to 482 for the papillary subtype. Comparative analysis of gene expression in adjacent normal tissues also identified subtype-specific genes, 38 in total. Gene set enrichment analysis identified oxidative phosphorylation as a biological function associated with papillary, and immune response - with solid subtype. Using data on differential expression between tumor and adjacent normal tissue among the subtype-specific genes and existing evidence for association with lung carcinogenesis, we have identified several candidate subtype-specific driver genes.
Conclusio: n We identified subtype-specific genes, biological functions, and potential drivers of subtype-specific carcinogenesis for LUAD subtypes. The study showed importance of gene expression in adjacent normal tissue for subtype-specific tumorigenesis.
Keywords: Gene expression; Lung adenocarcinoma (LUAD); Predominant subtypes.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Ethical approval was granted by the Institutional Ethics Committee of Baylor College of Medicine, Houston, TX and written informed consent was obtained for all study participants (H-35782). The study was conducted in accordance with the principles of the Declaration of Helsinki. Competing interests: The authors declare no competing interests.
Figures
References
-
- Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S, et al. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol. 2022;17(3):362–87. - PubMed
-
- Borczuk AC. Updates in grading and invasion assessment in lung adenocarcinoma. Mod Pathol. 2022;35(Suppl 1):28–35. - PubMed
-
- Li R, Li Z, Yang Z, Qiu B, Tan F, Xue Q, Gao S, He J. The presence of micropapillary and/or solid subtypes is an independent prognostic factor for patients undergoing curative resection for stage I lung adenocarcinoma with ground-glass opacity. Transl Lung Cancer Res. 2024;13(2):256–68. - PMC - PubMed
-
- Clay TD, Do H, Sundararajan V, Moore MM, Conron M, Wright GM, McLachlan SA, Dobrovic A, Russell PA. The clinical relevance of pathologic subtypes in metastatic lung adenocarcinoma. J Thorac Oncol. 2014;9(5):654–63. - PubMed
MeSH terms
Substances
Grants and funding
- R21 AI159379/AI/NIAID NIH HHS/United States
- ANR-23-IAHU-007/French National Research Agency
- R37 CA289419/CA/NCI NIH HHS/United States
- U19 CA203654/CA/NCI NIH HHS/United States
- R37 CA248478/CA/NCI NIH HHS/United States
- R01 CA275762/CA/NCI NIH HHS/United States
- RP200443/Cancer Prevention and Research Institute of Texas
- P30 CA125123/CA/NCI NIH HHS/United States
- R03 CA282953/CA/NCI NIH HHS/United States
- U19CA203654, R01CA285, U24 2U24OH009077-15-00, R01CA275762, R01CA243483, R21AI159379, R37 CA248478, CA289419-01,882, R03CA282953,/NH/NIH HHS/United States
- RR170048/Cancer Prevention and Research Institute of Texas
- R01 CA243483/CA/NCI NIH HHS/United States
- NCI-CA125123/Helis Medical Research Foundation
- U24 OH009077/OH/NIOSH CDC HHS/United States
- W81XWH-22-1-0657/U.S. Department of Defense
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
